标题
Pancreatic Cancer Chemoresistance to Gemcitabine
作者
关键词
-
出版物
Cancers
Volume 9, Issue 12, Pages 157
出版商
MDPI AG
发表日期
2017-11-17
DOI
10.3390/cancers9110157
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
- (2017) E Hessmann et al. GUT
- The role of stromal cancer-associated fibroblasts in pancreatic cancer
- (2017) Dagny von Ahrens et al. Journal of Hematology & Oncology
- Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
- (2017) Patricia Dauer et al. PANCREATOLOGY
- Chemoresistance in pancreatic cancer: Emerging concepts
- (2017) Manu Gnanamony et al. Oncology Letters
- Development of a Gemcitabine-Polymer Conjugate with Prolonged Cytotoxicity against a Pancreatic Cancer Cell Line
- (2017) Fanny Joubert et al. ACS Macro Letters
- A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine.
- (2017) C. McGuigan et al. JOURNAL OF CLINICAL ONCOLOGY
- Key role of pancreatic stellate cells in pancreatic cancer
- (2016) Srinivasa P. Pothula et al. CANCER LETTERS
- TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
- (2016) Rachel A. Hesler et al. CARCINOGENESIS
- Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Volker Ellenrieder et al. DIGESTION
- Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
- (2016) Sonja M. Wörmann et al. GASTROENTEROLOGY
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
- (2016) H. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells
- (2016) Michael Friberg Bruun Nielsen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells
- (2016) Vegard Tjomsland et al. NEOPLASIA
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study
- (2015) Knut J. Labori et al. ACTA ONCOLOGICA
- Does long-term survival exist in pancreatic adenocarcinoma?
- (2015) Myrte Zijlstra et al. ACTA ONCOLOGICA
- Biocompatible Glycopolymer Nanocapsules via Inverse Miniemulsion Periphery RAFT Polymerization for the Delivery of Gemcitabine
- (2015) Robert H. Utama et al. BIOMACROMOLECULES
- T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
- (2015) Ingunn M. Stromnes et al. CANCER CELL
- A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
- (2015) B. Venugopal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules
- (2015) Yanfen Fang et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance
- (2015) C. Duluc et al. EMBO Molecular Medicine
- An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
- (2015) Xinzhe Yu et al. International Journal of Nanomedicine
- Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies
- (2015) Andrei Maksimenko et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice
- (2015) Yanyun Xu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer
- (2015) Christopher Poon et al. JOURNAL OF CONTROLLED RELEASE
- Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
- (2015) Kentaro Minami et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2
- (2015) Nicolas Skrypek et al. Oncotarget
- Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells
- (2015) Masaya Jimbo et al. Oncotarget
- Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells
- (2015) Hui Zhang et al. Oncotarget
- Gemcitabine-Based Chemogene Therapy for Pancreatic Cancer Using Ad-dCK::UMK GDEPT and TS/RR siRNA Strategies
- (2015) Soukaina Réjiba et al. NEOPLASIA
- Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
- (2015) Hayato Fujita et al. NEOPLASIA
- Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
- (2014) Berna C. Özdemir et al. CANCER CELL
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Stromal reengineering to treat pancreas cancer
- (2014) I. M. Stromnes et al. CARCINOGENESIS
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
- (2014) Mara H. Sherman et al. CELL
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
- (2014) Lucas de Sousa Cavalcante et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: A comparison with its self-assembled nanoparticles
- (2014) Zahra Daman et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Transport properties of pancreatic cancer describe gemcitabine delivery and response
- (2014) Eugene J. Koay et al. JOURNAL OF CLINICAL INVESTIGATION
- Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
- (2014) Magdalena Slusarczyk et al. JOURNAL OF MEDICINAL CHEMISTRY
- Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
- (2014) CONGFEI WANG et al. ONCOLOGY REPORTS
- Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action
- (2014) Salah-Eddin Al-Batran et al. Oncology Research and Treatment
- Self-Assembling, Amphiphilic Polymer–Gemcitabine Conjugate Shows Enhanced Antitumor Efficacy Against Human Pancreatic Adenocarcinoma
- (2013) Deepak Chitkara et al. BIOCONJUGATE CHEMISTRY
- Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
- (2013) N. Awasthi et al. CARCINOGENESIS
- The development of orally administrable gemcitabine prodrugs with d-enantiomer amino acids: Enhanced membrane permeability and enzymatic stability
- (2013) Yasuhiro Tsume et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
- (2013) Minoti V. Apte et al. GASTROENTEROLOGY
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors
- (2013) F.E. Stuurman et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
- (2013) Raghu Kadaba et al. JOURNAL OF PATHOLOGY
- Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis
- (2013) Mert Erkan JOURNAL OF PATHOLOGY
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
- (2013) James D. Young et al. MOLECULAR ASPECTS OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase
- (2013) N Weizman et al. ONCOGENE
- CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
- (2013) A. Neesse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
- (2013) Vikash P. Chauhan et al. Nature Communications
- DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
- (2012) Yuriko Saiki et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression
- (2012) Saijie Zhu et al. BIOMATERIALS
- A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
- (2012) Y Nakai et al. BRITISH JOURNAL OF CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge
- (2012) Sau Wai Hung et al. CANCER LETTERS
- Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications
- (2012) Xiangyu Kong et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
- (2012) Michael A Jacobetz et al. GUT
- Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
- (2012) Elodie Moysan et al. MOLECULAR PHARMACEUTICS
- The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
- (2012) Mert Erkan et al. Nature Reviews Gastroenterology & Hepatology
- The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
- (2012) N Skrypek et al. ONCOGENE
- The Mucin MUC4 and Its Membrane Partner ErbB2 Regulate Biological Properties of Human CAPAN-2 Pancreatic Cancer Cells via Different Signalling Pathways
- (2012) Nicolas Jonckheere et al. PLoS One
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer
- (2012) Anastasios Dimou et al. Therapeutic Advances in Medical Oncology
- CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer Cells
- (2011) Y. D. Bhutia et al. CANCER RESEARCH
- In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles
- (2011) Brian R. Sloat et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1
- (2011) Woon-Gye Chung et al. JOURNAL OF CONTROLLED RELEASE
- Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy
- (2011) Geetanjali Arya et al. Nanomedicine-Nanotechnology Biology and Medicine
- Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer
- (2011) Soukaina Réjiba et al. Nanomedicine-Nanotechnology Biology and Medicine
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?
- (2011) Joseph Ciccolini et al. Nature Reviews Clinical Oncology
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices
- (2011) V. Allain et al. NUCLEIC ACIDS RESEARCH
- Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
- (2010) Hiroshi Maeda BIOCONJUGATE CHEMISTRY
- Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer
- (2010) Mallaredy Vandana et al. BIOMATERIALS
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
- (2010) Andries M. Bergman et al. INVESTIGATIONAL NEW DRUGS
- Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
- (2010) Savita Bisht et al. MOLECULAR CANCER THERAPEUTICS
- Delivering nanomedicine to solid tumors
- (2010) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Pancreatic cancer: understanding and overcoming chemoresistance
- (2010) Zhiwei Wang et al. Nature Reviews Gastroenterology & Hepatology
- Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer
- (2010) Shuji Komori et al. PANCREAS
- pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs
- (2010) Timothy K. Williams et al. PLoS One
- Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery
- (2010) Santosh Aryal et al. Small
- Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro
- (2009) Jin-ming Li et al. ACTA PHARMACOLOGICA SINICA
- Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
- (2009) S Bafna et al. BRITISH JOURNAL OF CANCER
- The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
- (2009) C. L. Costantino et al. CANCER RESEARCH
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- Clinical pharmacology and pharmacogenetics of gemcitabine
- (2009) Andrea Wong et al. DRUG METABOLISM REVIEWS
- Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
- (2009) Funamizu ONCOLOGY REPORTS
- Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
- (2009) Roland Andersson et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
- (2008) C. R. Patra et al. CANCER RESEARCH
- Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
- (2008) M. P. Kim et al. CLINICAL CANCER RESEARCH
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started